What Is the KLOW Peptide Blend? A Research Overview

KLOW is a research-peptide blend that combines four separate compounds — GHK-Cu, BPC-157, TB-500, and KPV — in a single lyophilized vial. It is essentially the GLOW blend (GHK-Cu + BPC-157 + TB-500) with KPV added. KLOW is not a single molecule, and there are no published studies on the “KLOW blend” itself; what exists is preclinical research on each component. All Bolt Peptide products are sold strictly for research use only (RUO) and are not for human consumption.

Quick facts

• Type: research peptide blend (multi-component)
• Components: GHK-Cu, BPC-157, TB-500, and KPV
• Also known as: GLOW + KPV
• Form: lyophilized (freeze-dried) powder
• Purity: ≥99% by HPLC, third-party tested
• Status: research use only — not for human or veterinary use

What is the KLOW blend?

KLOW is a combination rather than a distinct peptide. It packages four research peptides — the copper tripeptide GHK-Cu, the pentadecapeptide BPC-157, the actin-binding fragment TB-500, and the tripeptide KPV — into one vial. Because KLOW is a mixture, no peer-reviewed study has evaluated “KLOW” as such. The accurate way to understand it is to look at what each component has been studied for, summarized below with citations and links to each dedicated article.

The components

GHK-Cu (glycyl-L-histidyl-L-lysine–copper) is a naturally occurring copper-binding tripeptide. In cultured fibroblasts, the GHK–copper complex was reported to stimulate collagen synthesis at nanomolar concentrations [1]. This work is in-vitro only.

BPC-157 is a synthetic pentadecapeptide. In a rat-tissue and cell study, it accelerated tendon-explant outgrowth and increased tendon-fibroblast migration, linked to the FAK–paxillin pathway [2].

TB-500 corresponds to the active region of thymosin β4. In a rat wound model, thymosin β4 increased re-epithelialization and was associated with greater angiogenesis versus controls [3].

KPV (lysine-proline-valine) is a tripeptide from the C-terminus of α-MSH. In intestinal and immune cell models, nanomolar KPV inhibited NF-κB and MAP-kinase signaling via PepT1, and oral KPV reduced experimentally induced colitis in mice [4].

Research status and safety

Every effect above comes from in-vitro or animal research on the individual peptides. None establishes any outcome in humans, and combining the four does not create or imply a human benefit. The KLOW blend has not been evaluated by the FDA, is not a drug or supplement, and is intended exclusively for in-vitro laboratory research by qualified professionals — not for human or animal use.

Handling

KLOW ships as a lyophilized powder and should be stored cold and dark until use. Because it is freeze-dried, it must be reconstituted with an appropriate solvent before handling — see our guide on how to reconstitute a research peptide. Note that GHK-Cu’s copper complex gives reconstituted material a blue tint, which is expected. Browse related compounds in the catalog, and view this product here: View the KLOW Blend — research-grade, ≥99% pure.

FAQ

KLOW vs GLOW — what’s the difference? GLOW is a three-peptide blend (GHK-Cu, BPC-157, TB-500). KLOW adds a fourth component, KPV, to that same base.

Is there research on the KLOW blend specifically? No. There are no published studies on the four-peptide KLOW combination; the literature evaluates each component separately.

Can I use KLOW for personal recovery or skincare? No. KLOW is sold for research use only and is not for human use. We do not provide dosing or administration guidance.

References

1. Maquart FX, et al. Stimulation of collagen synthesis by the GHK-copper complex. FEBS Lett. 1988.
2. Chang CH, et al. The promoting effect of BPC 157 on tendon healing. J Appl Physiol. 2011.
3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
4. Dalmasso G, et al. PepT1-mediated KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.